Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET scan method could rival standard test for brain blood flow

NCT ID NCT06584747

Diagnosis Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a PET scan can measure brain blood vessel response to a drug called acetazolamide as well as the standard scintigraphy method. Nineteen adults with narrowed brain arteries will undergo both scans. The goal is to see if the newer PET approach is a reliable alternative for diagnosing blood flow problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Acetazolamide (Diamox)
What this could lead to
If successful, PET scans could replace the older method for assessing brain blood flow, offering a more accessible or detailed diagnostic option.
What could go wrong
This is a small, early-phase diagnostic study with only 19 participants. The PET method may not prove as accurate as the standard test, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

19 people

The number who actually took part.

Started

Jan 2025

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic stenosing cerebral vascular pathology (stenosis \> 70% on Doppler examination or angiography). * Patient aged over 18 years. * Patient who has voluntarily agreed to participate in the study and has signed the written informed consent. * Patient affiliated with a social security system. Exclusion Criteria: * Patient with stenosis less than 70% on Doppler examination or angiography. * Patient with a contraindication to 18F-FDG PET examinations: severe claustrophobia, poorly controlled diabetes during 18F-FDG PET examinations (fasting capillary blood glucose ≥ 11 mmol/L). * Patient with a contraindication to scintigraphy. * Patient with an allergy to sulfonamides (Acetazolamide DIAMOX®). * Patient enrolled in another clinical study with a specified exclusion period. * Minor patient. * Patient unable to give informed consent. * Vulnerable individuals

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebrovascular circulation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebrovascular circulation

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.